PL3784282T3 - Leczenie skojarzone zwłóknienia i/lub angiogenezy oka - Google Patents

Leczenie skojarzone zwłóknienia i/lub angiogenezy oka

Info

Publication number
PL3784282T3
PL3784282T3 PL19720551.1T PL19720551T PL3784282T3 PL 3784282 T3 PL3784282 T3 PL 3784282T3 PL 19720551 T PL19720551 T PL 19720551T PL 3784282 T3 PL3784282 T3 PL 3784282T3
Authority
PL
Poland
Prior art keywords
occular
angiogenesis
fibrosis
combination treatment
treatment
Prior art date
Application number
PL19720551.1T
Other languages
English (en)
Inventor
Stuart Alexander COOK
Sebastian Schaefer
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL3784282T3 publication Critical patent/PL3784282T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL19720551.1T 2018-04-27 2019-04-26 Leczenie skojarzone zwłóknienia i/lub angiogenezy oka PL3784282T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1806918.7A GB201806918D0 (en) 2018-04-27 2018-04-27 Combination treatment for eye fibrosis
PCT/EP2019/060772 WO2019207122A1 (en) 2018-04-27 2019-04-26 Combination treatment for eye fibrosis and/or angiogenesis

Publications (1)

Publication Number Publication Date
PL3784282T3 true PL3784282T3 (pl) 2025-12-15

Family

ID=62495028

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19720551.1T PL3784282T3 (pl) 2018-04-27 2019-04-26 Leczenie skojarzone zwłóknienia i/lub angiogenezy oka

Country Status (18)

Country Link
US (2) US20210238272A1 (pl)
EP (1) EP3784282B1 (pl)
JP (1) JP7540951B2 (pl)
KR (1) KR20210005125A (pl)
CN (1) CN112399856A (pl)
AU (1) AU2019258820B2 (pl)
BR (1) BR112020021985A2 (pl)
CA (1) CA3098340A1 (pl)
CL (1) CL2020002774A1 (pl)
DK (1) DK3784282T3 (pl)
EA (1) EA202092292A1 (pl)
ES (1) ES3037362T3 (pl)
GB (1) GB201806918D0 (pl)
HU (1) HUE073154T2 (pl)
MX (1) MX2020011401A (pl)
PH (1) PH12020551786A1 (pl)
PL (1) PL3784282T3 (pl)
WO (1) WO2019207122A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
EP3914621A1 (en) 2019-01-21 2021-12-01 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
BR112021021921A2 (pt) 2019-05-03 2021-12-28 Nat Univ Singapore Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
GB202009292D0 (en) * 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
EP4198055A4 (en) * 2020-08-13 2024-08-28 Sunshine Lake Pharma Co., Ltd. IL-11 ANTIBODY AND ITS USE
MX2024002611A (es) * 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN117964734B (zh) * 2024-03-04 2025-12-26 四川大学 一种重组人白介素-11突变体及其与化学分子偶联缀合物和其制备方法与应用
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311277A4 (en) * 2000-07-18 2004-08-25 Joslin Diabetes Center Inc METHODS OF FIBROSIS MODULATION
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
TW201427989A (zh) * 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2017141032A1 (en) * 2016-02-15 2017-08-24 Oxford University Innovation Limited Treatment of fibrotic disorders

Also Published As

Publication number Publication date
AU2019258820B2 (en) 2025-02-27
CN112399856A (zh) 2021-02-23
US20250326832A1 (en) 2025-10-23
MX2020011401A (es) 2021-01-08
WO2019207122A1 (en) 2019-10-31
EP3784282B1 (en) 2025-07-02
KR20210005125A (ko) 2021-01-13
ES3037362T3 (en) 2025-10-01
JP2021522272A (ja) 2021-08-30
DK3784282T3 (da) 2025-08-18
GB201806918D0 (en) 2018-06-13
EP3784282A1 (en) 2021-03-03
US20210238272A1 (en) 2021-08-05
PH12020551786A1 (en) 2021-05-10
CA3098340A1 (en) 2019-10-31
CL2020002774A1 (es) 2021-02-05
JP7540951B2 (ja) 2024-08-27
HUE073154T2 (hu) 2026-01-28
AU2019258820A1 (en) 2020-12-17
BR112020021985A2 (pt) 2021-01-26
EA202092292A1 (ru) 2021-04-06

Similar Documents

Publication Publication Date Title
PL3784282T3 (pl) Leczenie skojarzone zwłóknienia i/lub angiogenezy oka
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
PL3661954T3 (pl) Muteiny interleukiny 21 i sposoby leczenia
EP3692028A4 (en) INHIBITION OF UBIQUITIN-SPECIFIC PEPTIDASE 30
SI3716992T1 (sl) Uporaba antagonistov VEGF za zdravljenje angiogenih očesnih motenj
EP3600434A4 (en) TREATMENT OF PULMONAL HYPERTENSION
IL283200A (en) Combination treatment of nafld and nash
EP3781318A4 (en) EMULSIFIERS AND THEIR USES
LT3600270T (lt) Junginiai ir kompozicijos hematologiniams sutrikimams gydyti
IL281866A (en) Introducer devices and methods of use thereof
EP3672650A4 (en) Hydrogel for tissue engineering and bioprinting
PL3500287T3 (pl) Kompozycja zawierająca samoorganizujące się peptydy do stosowania do leczenia zapalenia przyzębia i/lub zapalenia tkanek okołowszczepowych
IL281938A (en) Stable semaglutide compositions and uses thereof
EP3324894A4 (en) LATERAL AND MEDIAL SWITCHING KNEE PROSTHESIS
EP3681369A4 (en) ARRANGEMENT FOR CLEANING AND DISINFECTING ENDOSCOPES
PL3810128T3 (pl) Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek
SG11202004005RA (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
PL3478310T3 (pl) Kompozycje przydatne w zapobieganiu i/lub leczeniu zapalenia i bólu stawów i kości oraz uszkodzenia chrząstki
EP3733177A4 (en) COMPOSITION FOR CORNEAL PROTECTION
IL274810A (en) Preparations and methods of use for the treatment of unusual inflammation of the secretory glands in the eye or in the external area of the eye
EP3632430A4 (en) AGENTS FOR THE PREVENTION OR TREATMENT OF SPINOCERBELLARY ATAXIA
EP3585395A4 (en) TREATMENT OF LOWER URINARY TRACT EPITHELIUM USING GLUCAGON-TYPE PEPTIDE 2
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
SG11201809811VA (en) Compositions and methods for treatment of inflammation or infection of the eye
EP3582817C0 (en) Tissue scaffold and scaffold composition